Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Female ejaculation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Female ejaculation. Displaying page 1 of 1.
    EudraCT Number: 2009-011855-40 Sponsor Protocol Number: OTB109059 Start Date*: 2009-11-26
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Doub...
    Medical condition: Premature ejaculation.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036596 Premature ejaculation LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001650-94 Sponsor Protocol Number: 191622-133 Start Date*: 2013-08-06
    Sponsor Name:Allergan Limited
    Full Title: An Exploratory Study of the Safety and Efficacy of BOTOX® for the Treatment of Premature Ejaculation
    Medical condition: Premature Ejaculation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10036596 Premature ejaculation PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000244-24 Sponsor Protocol Number: A3871027 Start Date*: 2004-08-18
    Sponsor Name:Pfizer AB
    Full Title: A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.
    Medical condition: Premature Ejaculation
    Disease: Version SOC Term Classification Code Term Level
    7.0 10036596 LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Completed) HU (Completed) IT (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-011411-21 Sponsor Protocol Number: BVF-324-302 Start Date*: 2009-07-17
    Sponsor Name:Biovail Laboratories International SRL, c/o Biovail Technologies Ltd
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Pre...
    Medical condition: Premature Ejaculation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036596 Premature ejaculation LLT
    Population Age: Adults Gender: Male
    Trial protocol: HU (Prematurely Ended) BG (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011410-18 Sponsor Protocol Number: BVF-324-301 Start Date*: 2009-07-29
    Sponsor Name:Biovail Laboratories International SRL, c/o Biovail Technologies Ltd
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Pre...
    Medical condition: Premature Ejaculation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036596 Premature ejaculation LLT
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Completed) SE (Prematurely Ended) ES (Completed) GB (Prematurely Ended) NL (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004150-51 Sponsor Protocol Number: A3871029 Start Date*: 2004-12-10
    Sponsor Name:Pfizer Limited
    Full Title: A Phase 2 multi centre, double blind, placebo controlled flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.
    Medical condition: Premature Ejaculation
    Disease: Version SOC Term Classification Code Term Level
    7.0 10036596 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001511-70 Sponsor Protocol Number: 44313 Start Date*: 2015-08-05
    Sponsor Name:Maastricht University Medical Center
    Full Title: Efficacy, safety and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutations related small fiber neuropathy: a randomized, double-blind, placebo controlled, crossover trial
    Medical condition: SCN9A mutation related small fiber neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004784-20 Sponsor Protocol Number: BER-PRO-2014-01 Start Date*: 2015-01-22
    Sponsor Name:Instituto Bernabeu
    Full Title: Subcutaneous progesterone ( Prolutex ) versus vaginal progesterone capsules (Progeffik) for endometrial preparation in fresh donated oocyte recipients: A prospective, randomized, single-blind, pi...
    Medical condition: Infertility. Assisted Reproductive Techniques. Fresh donated oocyte recipients
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038604 - Reproductive system and breast disorders 10021928 Infertility female PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003993-42 Sponsor Protocol Number: PKB171-02 Start Date*: 2017-03-17
    Sponsor Name:Prokrea BCN S.L.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of two concentrations of PKB171 against placebo in couples with asthenozoospermia who wish ...
    Medical condition: Asthenozoospermia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003063-21 Sponsor Protocol Number: HLX10-005-SCLC301 Start Date*: 2020-06-17
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Randomized, Double-Blind, Multicenter, Phase III Study to Compare Clinical Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemoth...
    Medical condition: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000743-31 Sponsor Protocol Number: 73841937NSC3003 Start Date*: 2020-09-23
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastat...
    Medical condition: EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002226-27 Sponsor Protocol Number: HLX10-020-SCLC302 Start Date*: 2022-11-17
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Pla...
    Medical condition: Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage I-III of the AJCC 8th edition of the cancer staging
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000633-40 Sponsor Protocol Number: 61186372NSC3001 Start Date*: 2020-11-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced...
    Medical condition: EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003064-50 Sponsor Protocol Number: HLX10-004-NSCLC303 Start Date*: 2020-06-17
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin-Nanoparticle Albumin-Bound (na...
    Medical condition: First-Line Therapy for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 23:44:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA